|
1
|
Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, Cross NCP, Gruenstein D, Najfeld V. A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. Acta Haematol 2019; 142:105-112. [PMID: 31063994 DOI: 10.1159/000498945] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Accepted: 02/10/2019] [Indexed: 11/19/2022]
Abstract
The JAK2V617F point mutation has been implicated in the pathogenesis of the vast majority of myeloproliferative neoplasms (MPNs), but translocations involving JAK2 have increasingly been identified in patients with JAK2V617F-negativeMPNs. Here, we present a case of a patient diagnosed with JAK2V617F-negativepolycythemia vera (PV) that transformed to the MPN-blast phase. Cytogenetic and FISH analysis revealed a novel translocation of t(1;9)(p36;p24.1), causing a PEX14-JAK2 gene fusion product. The t(1;9)(p36;p24.1) represents a new addition to the list of known translocations involving JAK2that have been identified in hematologic malignancies. Although the prognostic and treatment implications of JAK2 translocations in MPNs have not been elucidated, positive outcomes have been described in case reports describing the use of JAK inhibitors in these patients. Further research into the role of JAK2 translocations in the pathogenesis and outcomes of hematologic malignancies is warranted.
Collapse
Affiliation(s)
- Hannah Levavi
- Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA
| | | | - Bridget Marcellino
- Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA
| | - John Mascarenhas
- Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA
| | - Amy V Jones
- Faculty of Medicine, University of Southampton, Southampton, United Kingdom
| | - Nicholas C P Cross
- Faculty of Medicine, University of Southampton, Southampton, United Kingdom
| | - Diana Gruenstein
- Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA
| | - Vesna Najfeld
- Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA,
- Tisch Cancer Institute, New York, New York, USA,
| |
Collapse
|
|
2
|
The biogenesis protein PEX14 is an optimal marker for the identification and localization of peroxisomes in different cell types, tissues, and species in morphological studies. Histochem Cell Biol 2013; 140:423-42. [DOI: 10.1007/s00418-013-1133-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/29/2013] [Indexed: 01/09/2023]
|
|
3
|
Monoclonal Antibody Against Peroxisomal Biogenesis Factor 14. Hybridoma (Larchmt) 2012. [DOI: 10.1089/hyb.2012.0018.mab] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|